Form 4 for BSX Boston Scientific
Accepted 2023-07-06 00:00:00 ET · period of report 2023-07-03 · accession 0001225208-23-007373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-07-06 | 2023-07-03 | BSX | Morano Susan E | Dir | A - Grant | $0.00 | +2,082 | 2,082 | New | $0 |
| DM | 2023-07-06 | 2023-07-03 | BSX | Morano Susan E | Dir | A - Grant | $0.00 | +2,082 | 1,626 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-03 | A | A | 1,626 | $0.00 | 1,626 | D | — | — | (F1) Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of common stock on the date of grant. |
| 2 | Common | Common Stock | 2023-07-03 | A | A | 456 | $0.00 | 2,082 | D | — | — | (F2) Grant of restricted stock in lieu of 25% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. Reflects a value of approximately $24,428.88 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant. |
| 3 | Derivative | Deferred Stock Units | 2023-07-03 | A | A | 456 | $0.00 | 2,082 | D | — · — to — | 456 Common Stock | (F5) Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,428.87 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan. (F3) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 4 | Derivative | Deferred Stock Units | 2023-07-03 | A | A | 1,626 | $0.00 | 1,626 | D | — · — to — | 1,626 Common Stock | (F4) Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan. (F3) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |